Hair Thinning in Women: Hormonal Causes & Peptide Research

Hair thinning in women is remarkably prevalent yet rarely discussed openly. Female pattern hair loss (FPHL) — clinically termed androgenetic alopecia — affects approximately 40% of women by age 50 and up to 75% by age 65. Unlike male pattern baldness, which typically begins with a receding hairline and crown thinning, FPHL usually presents as diffuse thinning across the crown and top of the scalp, with preservation of the frontal hairline.

The psychological impact is significant. Research consistently shows that hair loss causes greater distress in women than in men, affecting self-esteem, social confidence, and mental health. A study in the *British Journal of Dermatology* found that women with FPHL had significantly higher rates of anxiety and depression than age-matched controls.

Despite its prevalence, FPHL is frequently dismissed or minimised by healthcare providers. Many women are told it is "just ageing" without investigation of potentially treatable underlying causes. Understanding the hormonal mechanisms involved is the first step toward effective management.

Hair follicles are exquisitely sensitive to hormonal changes. Several hormonal pathways can drive hair thinning in women:

Androgens (testosterone and DHT): Despite being often called "male hormones," women produce androgens too — just in smaller quantities. In genetically susceptible women, even normal androgen levels can cause hair follicle miniaturisation. Dihydrotestosterone (DHT), converted from testosterone by the enzyme 5-alpha reductase, is the primary culprit. It binds to androgen receptors in the hair follicle, shortening the growth (anagen) phase and producing progressively thinner, shorter hairs.

Oestrogen decline (menopause): Oestrogen has a protective effect on hair follicles, prolonging the anagen phase. During perimenopause and menopause, declining oestrogen levels shift the oestrogen-androgen balance, unmasking the effects of androgens on susceptible follicles. This is why many women first notice significant thinning around menopause.

Thyroid dysfunction: Both hypothyroidism and hyperthyroidism can cause diffuse hair loss. Thyroid hormones regulate hair follicle cycling, and imbalances disrupt the normal growth-rest cycle. Thyroid-related hair loss is typically diffuse and affects the entire scalp.

Polycystic ovary syndrome (PCOS): PCOS is characterised by elevated androgens, and hair thinning is one of its hallmark features. Women with PCOS may experience both scalp hair thinning and excess body/facial hair (hirsutism) — driven by the same androgen excess.

Iron deficiency: While not strictly hormonal, iron deficiency (with or without anaemia) is extremely common in premenopausal women and is associated with hair loss. Ferritin levels below 30 ng/mL are associated with increased hair shedding.

Post-pregnancy: The dramatic oestrogen drop after childbirth causes telogen effluvium — a temporary but often dramatic shedding episode 2–6 months postpartum. This typically resolves within 6–12 months.

Stress hormones: Chronic cortisol elevation can push hair follicles prematurely into the resting (telogen) phase, causing diffuse shedding.

Menopause represents a pivotal moment for many women's hair health. The hormonal shifts are significant and multifaceted:

What happens hormonally: During perimenopause (typically starting in the mid-40s), oestrogen and progesterone levels fluctuate unpredictably before declining. By post-menopause, oestrogen levels drop by approximately 90% compared to peak reproductive years. Meanwhile, adrenal androgens continue to be produced, creating a relative androgen excess.

The visible effects: Hair becomes thinner, finer, and less dense across the crown. The part line widens. Hair may become drier and more brittle. Growth rate slows. Some women also notice changes in hair texture (curlier or straighter than before).

HRT and hair: Hormone replacement therapy (HRT) that restores oestrogen levels may help slow menopause-related hair thinning in some women. However, the evidence is mixed, and the type of progestogen used matters — some synthetic progestogens have androgenic activity that could worsen hair loss. Body-identical progesterone (micronised progesterone) is generally considered hair-neutral.

Timeline: Menopause-related hair changes typically begin during perimenopause and continue for several years after the final period. The rate of thinning usually slows once hormone levels stabilise post-menopause, but regrowth of lost hair is limited without intervention.

What to discuss with your GP: If you are experiencing hair thinning around menopause, ask about: - Blood tests for thyroid function, iron studies, and hormonal profile - Whether HRT might be appropriate for you (considering overall menopause symptoms, not just hair) - Referral to dermatology if thinning is significant or progressive

Several peptides have been investigated for potential hair growth-promoting effects. As with most peptide applications, the evidence ranges from well-studied (GHK-Cu topically) to highly experimental:

GHK-Cu (copper peptide): The most evidence-supported peptide for hair applications. GHK-Cu has been shown to: - Stimulate hair follicle growth and increase follicle size in skin organ culture studies - Upregulate genes involved in hair growth (Wnt signalling pathway) - Increase dermal papilla cell proliferation - Show anti-inflammatory effects that may benefit the follicular environment

Topical GHK-Cu formulations are available in hair serums and scalp treatments. While not a dramatic hair regrowth treatment, it has reasonable supporting evidence for promoting a healthier scalp environment and supporting follicle function.

Follistatin: This glycoprotein binds and neutralises activin and myostatin — proteins that can negatively regulate hair growth. Follistatin gene therapy delivered via microneedling has been investigated by some clinics, though published clinical evidence is limited. The concept is scientifically plausible (follistatin is expressed in hair follicles and involved in the anagen-catagen transition), but human trial data is sparse.

TB-500 (Thymosin Beta-4): Animal studies have shown that thymosin beta-4 promotes hair growth, potentially by activating hair follicle stem cells. It may stimulate the transition from telogen (resting) to anagen (growth) phase. Human data specific to hair growth is lacking.

BPC-157: While primarily studied for tissue healing, BPC-157's effects on blood vessel formation and growth factor modulation have led some researchers to hypothesise benefits for follicular health. Direct evidence for hair growth is limited.

Important caveat: None of these peptides are approved medicines for hair loss in any country. The established, evidence-based treatments for FPHL remain minoxidil (topical), spironolactone (oral anti-androgen, off-label), and finasteride (used cautiously in post-menopausal women).

Before considering experimental peptide approaches, ensure you have explored established treatments:

Minoxidil (Regaine): The only topical treatment licensed for FPHL in the UK. Available over the counter as 2% solution or 5% foam. Works by prolonging anagen phase and increasing follicle size. Approximately 60% of women see improvement. Must be used continuously — stopping causes reversal within 3–6 months.

Spironolactone: An anti-androgen medication used off-label for FPHL. It blocks androgen receptors and reduces androgen production. Typically prescribed at 100–200 mg daily. Requires monitoring of potassium and blood pressure. Not suitable during pregnancy. Available through dermatologists.

Finasteride/Dutasteride: 5-alpha reductase inhibitors that reduce DHT production. Used off-label in post-menopausal women (strictly contraindicated in pregnancy and women of childbearing potential). Limited but growing evidence in women, primarily in post-menopausal patients.

Low-level laser therapy (LLLT): FDA-cleared devices (helmets, combs) that deliver low-level laser/LED light to the scalp. Moderate evidence for efficacy — a 2014 RCT showed significant improvement in hair density. Available for home use (£200–£600 for devices).

Platelet-rich plasma (PRP): Injections of concentrated growth factors from your own blood into the scalp. Multiple RCTs show improvements in hair density and thickness. Available privately (typically £300–£500 per session, 3–6 sessions recommended).

Nutritional optimisation: Ensure adequate iron (ferritin > 70 ng/mL is often recommended for hair health), vitamin D, zinc, biotin, and protein intake. Deficiencies in any of these can contribute to hair shedding.

When to see a dermatologist: If over-the-counter minoxidil has not produced results after 6–12 months, if hair loss is rapid or patchy (which may suggest alopecia areata, a different condition), or if you want to explore prescription treatments.

*This article is for educational purposes only. Consult your GP or a dermatologist for personalised assessment and treatment of hair loss.*